Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.

Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH.

J Surg Oncol. 2001 Feb;76(2):106-14.

PMID:
11223836
2.

Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.

Pestieau SR, Stuart OA, Sugarbaker PH.

Eur J Surg Oncol. 2000 Nov;26(7):696-700.

PMID:
11078617
3.

Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.

Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH.

Cancer Chemother Pharmacol. 2002 Jun;49(6):499-503. Epub 2002 Apr 26.

PMID:
12107555
4.

Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.

Glehen O, Stuart OA, Mohamed F, Sugarbaker PH.

Cancer Chemother Pharmacol. 2004 Jul;54(1):79-84. Epub 2004 Mar 26.

PMID:
15048586
5.

Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.

Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D.

Ann Surg Oncol. 2008 Jan;15(1):339-44. Epub 2007 Oct 18.

PMID:
17943387
6.

Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.

Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH.

Cancer Chemother Pharmacol. 1998;41(2):147-54.

PMID:
9443628
7.

Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.

Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH.

Cancer Chemother Pharmacol. 2003 Nov;52(5):405-10. Epub 2003 Jul 23.

PMID:
12879282
8.

Pharmacokinetics of heated intraperitoneal oxaliplatin.

Ferron G, Dattez S, Gladieff L, Delord JP, Pierre S, Lafont T, Lochon I, Chatelut E.

Cancer Chemother Pharmacol. 2008 Sep;62(4):679-83. Epub 2007 Dec 15.

PMID:
18084764
9.

Pharmacokinetics of intraperitoneal gemcitabine in a rat model.

Pestieau SR, Stuart OA, Chang D, Jacquet P, Sugarbaker PH.

Tumori. 1998 Nov-Dec;84(6):706-11.

PMID:
10080682
10.
11.

Oxaliplatin for chemotherapeutic treatment and prevention of experimental peritoneal carcinomatosis in rats comparing the intraperitoneal and intravenous application mode.

Hribaschek A, Meyer F, Ridwelski K, Kuester D, Lippert H.

Eur Surg Res. 2010;44(2):74-81. doi: 10.1159/000269932. Epub 2009 Dec 23.

PMID:
20051689
12.

Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.

Baur M, Drescher A, Gneist M, Dittrich C, Jaehde U.

Cancer Chemother Pharmacol. 2008 Jan;61(1):97-104. Epub 2007 Mar 30.

PMID:
17396265
13.

Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration.

Jacquet P, Stuart OA, Chang D, Sugarbaker PH.

Anticancer Drugs. 1996 Jul;7(5):596-603.

PMID:
8862729
14.

Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques.

Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, Chauffert B, Rat P.

Ann Surg Oncol. 2010 Jul;17(7):1957-63. doi: 10.1245/s10434-010-0937-z. Epub 2010 Feb 9.

15.

Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.

Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN.

Ann Surg Oncol. 2013 Apr;20(4):1101-4. doi: 10.1245/s10434-012-2790-8. Epub 2013 Mar 2.

16.

Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.

Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK.

Cancer Chemother Pharmacol. 2002 Dec;50(6):445-53. Epub 2002 Oct 16.

PMID:
12451470
17.

Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.

Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK.

Cancer Chemother Pharmacol. 2002 May;49(5):367-74. Epub 2002 Feb 20.

PMID:
11976830
18.

Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats.

Mas-Fuster MI, Ramon-Lopez A, Lacueva J, Compañ A, Más-Serrano P, Nalda-Molina R.

Cancer Chemother Pharmacol. 2017 Mar;79(3):621-627. doi: 10.1007/s00280-017-3244-6. Epub 2017 Feb 6.

PMID:
28168311
19.

High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.

Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P.

Ann Surg. 2012 Dec;256(6):1084-8. doi: 10.1097/SLA.0b013e3182582b38.

PMID:
22634898
20.

Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.

Sugarbaker PH, Stuart OA, Carmignani CP.

Cancer Chemother Pharmacol. 2006 May;57(5):703-8. Epub 2005 Aug 11.

PMID:
16096789

Supplemental Content

Support Center